Considering how poor they were, it's amazing that they came as close as they did come to the analyst's revenue prediction. Those numbers were mostly the aftermath of the Bulgarian tissue affair, and I don't think that undue importance should be attributed to them, when weighed against the higher margin growth initiatives which are well underway.